Quantcast
Last updated on April 18, 2014 at 9:27 EDT

Latest Trovagene Inc. Stories

2014-04-08 12:31:41

Study results show correlation between mutational status and treatment response, as well as concordance between BRAF V600E mutation assay and tissue biopsy at baseline SAN DIEGO, April 8, 2014 /PRNewswire/ -- Clinical study results presented today at the American Association for Cancer Research (AACR) Annual Meeting demonstrate the ability of Trovagene's (NASDAQ: TROV) molecular diagnostic platform to detect and monitor BRAF V600E mutations in cancer patients. The results were...

2014-04-01 08:28:44

SAN DIEGO, April 1, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that clinical data from a study using the company's cancer monitoring platform for the detection and longitudinal monitoring of BRAF V600E mutations will be the subject of a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California....

2014-03-26 08:29:02

SAN DIEGO, March 26, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Charles Cantor, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Cantor, one of the leaders of the Human Genome Project, has published more than 400 peer reviewed articles, authored and co-authored more than 50 U.S. and international patents, and is also an author of the first genomics textbook, Genomics: The Science and...

2014-03-19 08:28:52

Partnership Seeks To Establish Clinical and Health Economic Benefits of Trovagene's Urine-Based Cell-Free Molecular Diagnostics for Potential Adoption in Cancer Management Strategies SAN DIEGO and BALTIMORE, March 19, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) and Catholic Health Initiatives Center for Translational Research (CTR) today announced they have entered into a strategic partnership to conduct clinical validation studies, clinical utility studies, health economic...

2014-03-17 16:28:46

Expanding Cancer Monitoring Platform with Additional Oncogene Mutation Assays, Building Clinical Evidence to Facilitate Broad Adoption SAN DIEGO, March 17, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013. http://photos.prnewswire.com/prnvar/20120620/LA28014LOGO "In 2013, we transitioned from a technology-driven company to one focused on building a body...

2014-03-17 08:29:15

Company leveraging the scalability of its proprietary platform and next generation sequencing to introduce a full line of multiplexed urine-based oncogene mutation assays with superb sensitivity SAN DIEGO, March 17, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it has released its first multiplexed oncogene mutation assay, integrating the Company's proprietary sample preparation and primer technologies with...

2014-03-03 08:31:25

SAN DIEGO, March 3, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the quarter and year ended December 31, 2013 on Monday, March 17, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time). http://photos.prnewswire.com/prnvar/20120620/LA28014LOGO Trovagene's management team will host a conference call on Monday, March 17, 2014 at 5:00 p.m. Eastern...

2014-02-19 08:31:25

SAN DIEGO, Feb. 19, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Dr. Rodney S. Markin has joined the Company's Board of Directors. Dr. Markin is a hepatic pathologist by training, and is a leading authority in the field of laboratory automation. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) "We are very pleased that Rod has joined our board of directors" stated Antonius Schuh, Ph.D.,...

2014-02-06 08:28:22

2014 BIO CEO & Investor Conference and Leerink Global Healthcare Conference SAN DIEGO, Feb. 6, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the following 2014 healthcare and investor conferences next week in New York: BIO CEO & Investor Conference and Leerink Global Healthcare Conference. (Logo:...

2014-01-06 04:21:59

SAN DIEGO and THE WOODLANDS, Texas, Jan. 6, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, and US Oncology Research, one of the largest community-based research programs in the United States, announced today that they have entered into a Clinical Study Agreement to examine the utility of quantitative urine-based KRAS mutation detection and monitoring in pancreatic cancer patients. US Oncology Research draws from a network of...